Gout.
Journal
Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R
Informations de publication
Date de publication:
15 05 2021
15 05 2021
Historique:
received:
30
03
2020
revised:
22
09
2020
accepted:
07
10
2020
pubmed:
3
4
2021
medline:
22
7
2021
entrez:
2
4
2021
Statut:
ppublish
Résumé
Gout is a common and treatable disease caused by the deposition of monosodium urate crystals in articular and non-articular structures. Increased concentration of serum urate (hyperuricaemia) is the most important risk factor for the development of gout. Serum urate is regulated by urate transporters in the kidney and gut, particularly GLUT9 (SLC2A9), URAT1 (SLC22A12), and ABCG2. Activation of the NLRP3 inflammasome by monosodium urate crystals with release of IL-1β plays a major role in the initiation of the gout flare; aggregated neutrophil extracellular traps are important in the resolution phase. Although presenting as an intermittent flaring condition, gout is a chronic disease. Long-term urate lowering therapy (eg, allopurinol) leads to the dissolution of monosodium urate crystals, ultimately resulting in the prevention of gout flares and tophi and in improved quality of life. Strategies such as nurse-led care are effective in delivering high-quality gout care and lead to major improvements in patient outcomes.
Identifiants
pubmed: 33798500
pii: S0140-6736(21)00569-9
doi: 10.1016/S0140-6736(21)00569-9
pii:
doi:
Substances chimiques
Gout Suppressants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1843-1855Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.